Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2017)Supportive care in pancreatic ductal adenocarcinoma Clin Transl Oncol 19 1293-1302

[3] Jemal A(2016)Epidemiology of pancreatic cancer World J Gastroenterol 22 9694-9705

[4] Laquente B(2018)Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes World J Gastroenterol 24 4846-4861

[5] Calsina-Berna A(2014)Pancreatic adenocarcinoma N Engl J Med 371 1039-1049

[6] Carmona-Bayonas A(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825

[7] Jiménez-Fonseca P(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703

[8] Peiró I(2014)Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine refractory pancreatic cancer: outcomes from the CONKO-003 trial J Clin Oncol 32 2423-2429

[9] Carrato A(2016)Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet 387 545-557

[10] Ilic M(2006)Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481-485

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2017)Supportive care in pancreatic ductal adenocarcinoma Clin Transl Oncol 19 1293-1302

[3] Jemal A(2016)Epidemiology of pancreatic cancer World J Gastroenterol 22 9694-9705

[4] Laquente B(2018)Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes World J Gastroenterol 24 4846-4861

[5] Calsina-Berna A(2014)Pancreatic adenocarcinoma N Engl J Med 371 1039-1049

[6] Carmona-Bayonas A(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825

[7] Jiménez-Fonseca P(2013)Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369 1691-1703

[8] Peiró I(2014)Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine refractory pancreatic cancer: outcomes from the CONKO-003 trial J Clin Oncol 32 2423-2429

[9] Carrato A(2016)Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Lancet 387 545-557

[10] Ilic M(2006)Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481-485